| Literature DB >> 34570314 |
Shoko Matsumoto1, Moeko Nagai2, Dieu An Dang Luong2, Hoai Dung Thi Nguyen3, Dung Thi Nguyen3, Trang Van Dinh3, Giang Van Tran3,4, Junko Tanuma2, Thach Ngoc Pham3, Shinichi Oka2.
Abstract
Coronavirus disease 2019 (COVID-19) and associated social responses may uniquely affect people living with HIV (PLHIV). SARS-CoV-2 antibody testing and a cross-sectional survey on COVID-19's socio-behavioral impacts were conducted among a large PLHIV cohort in Hanoi, Vietnam. We examined anonymous antibody test results for 1243 PLHIV (99.8%) from whom plasma was obtained and completed surveys were collected in June/July 2020, just after the end of the first COVID-19 outbreak and nationwide lockdown. Three participants (0.2%) tested positive for anti-SARS-CoV-2 IgG antibodies. HIV treatment was generally maintained without antiretroviral therapy interruption, but COVID-19 had substantial impacts on economic security and risky health behaviors among PLHIV, which may have amplified psychological stress. These findings highlight the need for continuous monitoring of COVID-19's impacts on PLHIV and for efforts to mitigate these impacts.Entities:
Keywords: Antibody; COVID-19; HIV; Mental health; SARS-CoV-2
Mesh:
Year: 2021 PMID: 34570314 PMCID: PMC8475817 DOI: 10.1007/s10461-021-03464-w
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165
Characteristics of the study participants
| % | ||
|---|---|---|
| All participants | 1243 | 100.0 |
| Sex | ||
| Male | 717 | 57.7 |
| Female | 526 | 42.3 |
| Age (years) | ||
| Median (IQR) | 42 (37–46) | |
| < 37 | 252 | 21.6 |
| 37–41 | 314 | 27.0 |
| 42–45 | 279 | 24.0 |
| ≥ 46 | 320 | 27.5 |
| Residence | ||
| Hanoi | 574 | 46.2 |
| Other | 669 | 53.8 |
| Marital status | ||
| Married | 818 | 65.8 |
| Unmarried | 86 | 6.9 |
| Widowed or divorced | 201 | 16.2 |
| N/A | 138 | 11.1 |
| Educational attainmenta | ||
| Low | 307 | 24.7 |
| Middle | 328 | 26.4 |
| High | 468 | 37.7 |
| N/A | 140 | 11.3 |
| Employment before COVID-19 | ||
| Full-time employment as an employee | 417 | 33.6 |
| Part-time employment as an employee | 74 | 6.0 |
| Working full-time but not as an employee (self-employed) | 262 | 21.1 |
| Working part-time but not as an employee (self-employed) | 175 | 14.1 |
| Jobless and not working at all (including retirement) | 176 | 14.2 |
| N/A | 139 | 11.2 |
| History of IDU | ||
| No (never used injection drugs) | 968 | 77.9 |
| Yes (ever used injection drugs) | 275 | 22.1 |
| Time since ART initiation (years) | 108 (90,144) | |
| < 9 | 613 | 49.3 |
| ≥ 9 | 630 | 50.7 |
IQR interquartile range, N/A not available, COVID-19 Coronavirus disease 2019, IDU injection drug use, ART antiretroviral therapy
aEducational attainment: low—never attended school, primary school, or junior high school; middle—high school; high—vocational school/college or university
Incidence of SARS-CoV-2 infection
| Variable | n | % |
|---|---|---|
| History of SARS-CoV-2 infection (self-reported) | ||
| Never diagnosed or quarantined | 1237 | 99.5 |
| Diagnosed (by PCR test) | 0 | 0.0 |
| Quarantined | 0 | 0.0 |
| N/A | 6 | 0.5 |
| Anti-SARS-CoV-2 IgG antibodies | ||
| Positive | 3 | 0.2 |
| Negative | 1228 | 98.8 |
| N/A | 12 | 1.0 |
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, PCR polymerase chain reaction, N/A not available
Descriptive analysis of the impacts of COVID-19: prevention, HIV continuum of care, economic security, and risky health behaviors
| Variable | % | |
|---|---|---|
| Protective behaviors against COVID-19 | ||
| Not practiced | 26 | 2.1 |
| Practiced | 1192 | 95.9 |
| N/A | 25 | 2.0 |
| Description of protective behaviors against COVID-19a (among those who practiced protective behaviors) | ||
| Social distancing | 1073 | 86.3 |
| Hand washing | 1076 | 86.6 |
| Wearing a mask | 1119 | 90.0 |
| Other | 33 | 2.7 |
| Social contactb with other people during COVID-19 | ||
| No change | 576 | 46.3 |
| Decreased | 622 | 50.0 |
| Increased | 10 | 0.8 |
| N/A | 35 | 2.8 |
| Access to ART during COVID-19 | ||
| Continued receiving ART at the NHTD | 1074 | 86.4 |
| Temporarily received ART at another hospital | 116 | 9.3 |
| N/A | 53 | 4.3 |
| Change of ART regimen at the other hospital (among those who received ART at another hospital) | ||
| Changed | 8 | 6.9 |
| No change | 99 | 85.3 |
| N/A | 9 | 7.8 |
| Discontinuation of ART because of COVID-19 | ||
| Not discontinued | 1187 | 95.5 |
| Discontinued | 13 | 1.1 |
| N/A | 43 | 3.5 |
| Duration of ART discontinuation (among those who discontinued ART) | ||
| < 30 days | 4 | 30.8 |
| 30 days | 4 | 30.8 |
| 60 days | 2 | 15.4 |
| N/A | 3 | 23.1 |
| Support for continuing ART and HIV care during COVID-19 | ||
| Not received | 206 | 16.6 |
| Received | 963 | 77.5 |
| N/A | 74 | 6.0 |
| Source of support (among those who received support)a | ||
| Government agency (e.g., VAAC) | 145 | 15.1 |
| NHTD health care staff members | 903 | 93.8 |
| Other PLHIV | 81 | 8.4 |
| Other | 43 | 4.5 |
| Change in job status because of COVID-19 | ||
| No change | 942 | 75.8 |
| Lost jobs | 174 | 14.0 |
| Started working | 11 | 0.9 |
| Changed jobs | 56 | 4.5 |
| Changed job status, but no detail provided | 26 | 2.9 |
| N/A | 34 | 2.7 |
| Change in household income because of COVID-19 | ||
| No change | 894 | 71.9 |
| Increased | 10 | 0.8 |
| Decreased | 251 | 20.2 |
| Change in income, but no detail provided | 56 | 4.5 |
| N/A | 32 | 2.6 |
| Household income before COVID-19 (among those with a reduction in household income) | ||
| Median (IQR), VND | 8,000,000 (5,000,000 to 10,000,000) | |
| Amount of change in household income (among those with a reduction in household income) | ||
| Median (IQR), VND | − 3,000,000 (− 5,000,000 to − 2,000,000) | |
| Change in alcohol consumption (compared with the amount before COVID-19) | ||
| Non-drinker or no change | 1009 | 81.2 |
| Decreased | 199 | 16.0 |
| Increased | 7 | 0.6 |
| N/A | 28 | 2.3 |
| Change in drug use (compared with the amount before COVID-19) | ||
| Non-drug user | 1207 | 97.1 |
| No change | 1 | 0.1 |
| Decreased | 9 | 0.7 |
| Increased | 0 | 0.0 |
| N/A | 26 | 2.1 |
| Change in condom use (compared with usage before COVID-19) | ||
| No change | 940 | 75.6 |
| Decreased | 16 | 1.3 |
| Increased | 56 | 4.5 |
| N/A | 231 | 18.6 |
| Change in the number of sex partners (compared with the number before COVID-19) | ||
| No change | 848 | 68.2 |
| Increased | 22 | 1.8 |
| Decreased | 66 | 5.3 |
| N/A | 307 | 24.7 |
| General distress (DASS-21-V) | ||
| Mean ± SD | 9.2 (18.2) | |
| Distressed (DASS-21-V ≥ 34) | 95 | 7.6 |
| Not distressed (DASS-21-V < 34) | 1000 | 80.5 |
| N/A | 148 | 11.9 |
COVID-19 Coronavirus disease 2019, N/A not available, ART antiretroviral therapy, VAAC Ministry of Health, Vietnam Administration of HIV/AIDS Control, NHTD National Hospital for Tropical Diseases, PLHIV people living with HIV, IQR interquartile range, VND Vietnamese dong, DASS-21-V the Vietnamese version of the Depression, Anxiety, and Stress Scale-21
aMultiple responses were allowed
bSocial contact included non-face-to-face contacts through email, phone, or social networking services
HIV viral load, loss to follow-up, and general distress before and after the COVID-19 outbreak
| Before COVID-19a | After COVID-19a | |||
|---|---|---|---|---|
| % | % | |||
| HIV viral load (copies/mL) | ||||
| Median (range)b | 0 (0 to 265,000) | 0 (0 to 118,000) | ||
| < 20 | 1174 | 94.5 | 1137 | 91.5 |
| 20–199 | 56 | 4.5 | 99 | 8.0 |
| 200–999 | 7 | 0.6 | 2 | 0.2 |
| ≥ 1000 | 6 | 0.5 | 5 | 0.4 |
| Loss to follow-upc | ||||
| Number of participants on the first day of follow-up | 1344 | 100.0 | 1288 | 100.0 |
| Number of participants lost to follow-up during a 6-month follow-up period | 24 | 1.8 | 18 | 1.4 |
COVID-19 Coronavirus disease 2019
aThe 6-month follow-up periods before and after the COVID-19 epidemic were from June 1, 2019, to November 30, 2019, and from December 1, 2019, to May 31, 2020, respectively
bTo calculate median HIV viral load, the results of undetectable and < 20 copies/mL were treated as 0 copies/mL and 10 copies/mL, respectively
cLoss to follow-up was defined as a patient missing a scheduled visit without a known reason
Results of univariate logistic regression analyses: factors associated with detectable HIV viral load and general distress after the COVID-19 outbreak
| Detectable HIV viral loada (> 20 copies/mL) | General distressa (DASS-21-V ≥ 34) | |||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Protective behaviors against COVID-19 | ||||
| Not practiced | 1.00 | 0.22 | 1.00 | 0.17 |
| Practiced | 0.51 (0.17–1.51) | 0.47 (0.16–1.40) | ||
| Social contactb with other people during COVID-19 | ||||
| No change | 1.00 | 0.41 | 1.00 | 0.98 |
| Decreased | 0.76 (0.51–1.14) | 0.98 (0.64–1.51) | ||
| Increased | – | 1.18 (0.15–9.57) | ||
| Access to ART during COVID-19 | ||||
| Continued receiving ART at the NHTD | 1.00 | 0.35 | 1.00 | 0.02 |
| Temporarily received ART at another hospital | 0.69 (0.31–1.52) | 2.06 (1.12–3.81) | ||
| Discontinuation of ART because of COVID-19 | ||||
| Not discontinued | 1.00 | 0.91 | 1.00 | 0.98 |
| Discontinued | 0.89 (0.11–6.89) | – | ||
| Support for continuing ART and HIV care during COVID-19 | ||||
| Not received | 1.15 (0.68–1.95) | 0.60 | 2.21 (1.35–3.60) | < 0.01 |
| Received | 1.00 | 1.00 | ||
| Change in job status because of COVID-19 | ||||
| No change | 1.00 | 0.81 | 1.00 | < 0.0001 |
| Lost jobs | 0.66 (0.35–1.27) | 3.43 (2.06–5.70) | ||
| Started working | – | 4.93 (0.97–25.0) | ||
| Changed jobs | 0.96 (0.38–2.48) | 2.41 (1.03–5.60) | ||
| Changed job status, but no detail provided | 0.82 (0.19–3.52) | 2.61 (0.74–9.18) | ||
| Change in household income because of COVID-19 | ||||
| No change | 1.00 | 0.97 | 1.00 | < 0.0001 |
| Increased | – | 5.31 (1.04–27.02) | ||
| Decreased | 1.06 (0.65–1.72) | 3.32 (2.08–5.29) | ||
| Changed income, but no detail provided | 0.81 (0.28–2.28) | 2.86 (1.22–6.73) | ||
| Change in alcohol consumption (compared with the amount before COVID-19) | ||||
| Non-drinker or no change | 1.00 | 0.54 | 1.00 | 0.06 |
| Decreased | 1.33 (0.81–2.21) | 1.77 (1.06–2.95) | ||
| Increased | – | 2.96 (0.33–26.82) | ||
| Change in drug use (compared with the amount before COVID-19) | ||||
| Non-drug user | 1.00 | 0.37 | 1.00 | 1.00 |
| No change | – | – | ||
| Decreased | 3.13 (0.64–15.26) | – | ||
| Increased | – | – | ||
| Change in condom use (compared with usage before COVID-19) | ||||
| No change | 1.00 | 0.44 | 1.00 | < 0.01 |
| Decreased | 0.73 (0.10–5.57) | 2.20 (0.48–10.04) | ||
| Increased | 0.40 (0.10–1.69) | 3.56 (1.69–7.52) | ||
| Change in the number of sex partners (compared with the number before COVID-19) | ||||
| No change | 1.00 | 0.72 | 1.00 | < 0.0001 |
| Decreased | 0.82 (0.32–2.10) | 3.63 (1.80–7.29) | ||
| Increased | 0.48 (0.06–3.59) | 4.32 (1.50–12.41) | ||
COVID-19 Coronavirus disease 2019, OR odds ratio, CI confidence interval, DASS-21-V The Vietnamese version of the Depression, Anxiety, and Stress Scale-21 (DASS-21), ART antiretroviral therapy, NHTD National Hospital for Tropical Diseases
– indicates that the odds ratio could not be calculated because the number of participants in the category was too small
aHIV viral load and DASS-21-V score were obtained in June or July 2020, after the first outbreak of COVID-19
bSocial contact included non-face-to-face contact through email, phone, or social networking services